Pomerantz Law Firm Investigates Galectin Therapeutics Inc.
In an important development for investors of Galectin Therapeutics Inc., the renowned Pomerantz LLP law firm has initiated an investigation. This inquiry focuses on the potential engagement of the company and its executives in practices that may be deemed unlawful or fraudulent. As a publicly listed company under NASDAQ: GALT, Galectin's actions are drawing significant attention.
The investigation aims to uncover whether the leadership at Galectin Therapeutics has been involved in any violations of securities laws. Investors concerned about these allegations may wish to seek further information and support regarding their rights and options.
FDA Communication and Market Reaction
Adding to the urgency of the situation, Galectin recently made headlines following a communication from the U.S. Food and Drug Administration (FDA) relating to its drug, belapectin. Initially, the FDA was expected to conduct a meeting to discuss the development plans for this potential treatment, which is designed to inhibit galectin-3. However, this progression has taken a different turn.
On December 19, 2025, the company revealed that the FDA had opted to respond in writing instead of holding a live meeting. While Galectin maintained a narrative of alignment on the proposed patient population for future trials, critical elements regarding the trial design are still pending resolution. This news significantly affected Galectin's stock price, which plummeted by 28.9%, closing at $4.38 per share on the announcement date.
A History of Pomerantz LLP and Its Impact
Pomerantz LLP is well-regarded in the legal industry, especially in the realms of corporate, securities, and antitrust litigation. The firm has established a strong reputation over its 85 years of operation, guided by its founder, Abraham L. Pomerantz, who is often referred to as the dean of the class action bar.
Throughout its history, Pomerantz has championed the rights of victims affected by securities fraud and corporate misconduct, successfully recovering substantial damages for its clients. Their focus on protecting investor rights and navigating complex securities laws positions them as a powerful ally for those potentially impacted by the recent events at Galectin Therapeutics.
What This Means for Investors
The unfolding circumstances around Galectin Therapeutics Inc. serve as a critical reminder for investors about the inherent risks associated with investing in development-stage biopharmaceutical companies. The unexpected FDA communication and subsequent reaction in the stock market could serve as a harbinger for challenges that lie ahead.
Investors should remain vigilant and consider their options given the legal investigation led by Pomerantz LLP. The firm is inviting stakeholders to reach out for more information regarding any claims they might have related to the situation. Engaging with legal experts may provide additional insights into how to navigate these uncertain waters.
Frequently Asked Questions
What sparked the investigation by Pomerantz LLP?
The investigation was initiated due to concerns over possible securities fraud or unlawful business practices by Galectin Therapeutics Inc. and its leadership.
How did the stock market respond to the FDA’s announcement?
Following the FDA's announcement regarding its communication format, Galectin's stock price fell dramatically by 28.9%, closing at $4.38.
What is the main drug involved in this case?
The drug at the center of the discussion is belapectin, which is an investigational galectin-3 inhibitor developed by Galectin Therapeutics.
Who can investors contact regarding their claims?
Investors can reach out to Danielle Peyton at Pomerantz LLP to discuss potential claims and seek guidance on how to proceed.
What is the history of Pomerantz LLP?
Pomerantz LLP has been a leading firm in securities class actions for over 85 years, representing investors and recovering significant damages on their behalf.
